P53 in bladder cancer: mechanism of action, prognostic value, and target for therapy.
Slaton
J W
JW
Departments of Urology and Genitourinary Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
Benedict
W F
WF
Dinney
C P
CP
D000283:Administration, Intravesical; D020533:Angiogenesis Inhibitors / Q000032:analysis; D017209:Apoptosis / Q000187:drug effects / Q000276:immunology; D001500:BCG Vaccine / Q000008:administration & dosage / Q000627:therapeutic use; D002278:Carcinoma in Situ / Q000175:diagnosis / Q000276:immunology / Q000628:therapy; D002295:Carcinoma, Transitional Cell / Q000175:diagnosis* / Q000276:immunology / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D015653:Cystectomy; D016228:Endothelial Growth Factors / Q000032:analysis; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D007150:Immunohistochemistry; D007167:Immunotherapy / Q000379:methods; D008222:Lymphokines / Q000032:analysis; D009687:Nuclear Proteins; D011379:Prognosis; D011518:Proto-Oncogene Proteins / Q000032:analysis; D051736:Proto-Oncogene Proteins c-mdm2; D019700:Thrombospondin 1 / Q000032:analysis; D016159:Tumor Suppressor Protein p53 / Q000032:analysis* / Q000494:pharmacology / Q000627:therapeutic use*; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis* / Q000276:immunology / Q000628:therapy*; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D020741:rho GTP-Binding Proteins / Q000032:analysis
D020533:Angiogenesis Inhibitors; D001500:BCG Vaccine; D016228:Endothelial Growth Factors; D008222:Lymphokines; D009687:Nuclear Proteins; D011518:Proto-Oncogene Proteins; D019700:Thrombospondin 1; D016159:Tumor Suppressor Protein p53; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2; D020741:rho GTP-Binding Proteins